First Human Shamonda Virus Case Confirmed in France

French health authorities confirmed on Thursday, October 22, 2026, the first documented human case of the Shamonda virus in a severely immunocompromised patient in Lyon who died in early October 2026[1][3][4]. This discovery makes the patient the first known human infected with the arbovirus, which was previously considered non-transmissible to humans[2][5].

This event changes the understanding of a virus previously thought to affect only livestock, highlighting the ongoing risk of zoonotic diseases for public health[10][11]. While authorities state no immediate risk to the general public, the case prompts investigations into how such viruses cross species barriers and the implications for vulnerable individuals[4][7][11].

What the records show

The French Ministry of Health and the Ministry of Agriculture issued a joint statement asserting that "no health risk to the general public has been identified to date"[4][5][7]. They described the human infection as an "exceptional case involving a severely immunocompromised patient" undergoing treatment for a serious illness at the Hospices Civils de Lyon[4][10]. Preliminary investigations indicated that cerebral complications observed in the patient before death were "very likely linked to the Shamonda virus infection"[5][8]. Clinical, biological, and epidemiological investigations continue to determine if the virus directly caused or significantly contributed to the patient's death and how the infection was acquired[7][8][10]. The Shamonda virus is typically transmitted by biting midges of the genus Culicoides[5][12]. It is an Orthobunyavirus[9][12].

The timeline

The Shamonda virus was first identified in Nigeria in the mid-1960s and has since been reported sporadically in cattle across parts of Africa and Japan[5][9][12]. The virus made its first appearance in Europe in summer 2026, with detections in cattle in countries including Germany, Switzerland, and eastern France[7][10][12]. The leading hypothesis for the human infection is that the patient was infected through an insect bite in eastern France, an area where the virus had circulated among animals during the spring and summer of 2026[5][7][10].

What changed and for whom

Before this case, the Shamonda virus had been investigated primarily as an animal virus, with no documented human infection[10][12]. This first human case changes the known host range of the pathogen and has led to increased attention on zoonotic disease surveillance[10][11]. The patient's severely immunocompromised state made them more susceptible to infection than the general population, according to authorities[7][9]. The World Health Organization (WHO) and the European Centre for Disease Prevention and Control (ECDC) have been notified of the case, and the ECDC is in contact with French authorities and European partners to investigate potential public health implications[5][7][12]. Over 60% of human pathogens are zoonotic, and approximately 75% of emerging infectious diseases originate in animals[11].

What the subject has said publicly

In a joint statement, the French Ministry of Health and Ministry of Agriculture stated, "no health risk to the general public has been identified to date"[4][5][7]. They further emphasized that "this was an exceptional case involving a severely immunocompromised patient" and that current knowledge suggests no risk to the general population[4][5]. The ECDC confirmed it is "carefully monitoring the situation" and is "in contact with the French authorities and European partners to investigate the potential public health implications"[7].

What we could not confirm

We could not confirm the specific midge species involved in the transmission of the virus to the human patient[5]. The exact route of infection, including whether it was a particular insect bite, farm, or other source, has not been definitively established[10][12]. It also remains under investigation whether the virus directly caused the patient's death or only contributed to it[7][12]. There are currently no commercially available vaccines against the Shamonda virus[7].